Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

AMGN

Amgen (AMGN)

Amgen Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:AMGN
일자시간출처헤드라인심볼기업
2024/12/1106:30PR Newswire (US)AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDENDNASDAQ:AMGNAmgen Inc
2024/12/0800:00PR Newswire (US)BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)NASDAQ:AMGNAmgen Inc
2024/12/0708:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
2024/12/0523:00PR Newswire (US)AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINANASDAQ:AMGNAmgen Inc
2024/12/0409:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
2024/12/0306:00PR Newswire (US)AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
2024/11/3006:30PR Newswire (US)AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCENASDAQ:AMGNAmgen Inc
2024/11/2621:05PR Newswire (US)AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDYNASDAQ:AMGNAmgen Inc
2024/11/2621:00PR Newswire (US)AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAMNASDAQ:AMGNAmgen Inc
2024/11/2106:00PR Newswire (US)AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENTNASDAQ:AMGNAmgen Inc
2024/11/1506:00PR Newswire (US)AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024NASDAQ:AMGNAmgen Inc
2024/11/1405:27PR Newswire (US)MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRMNASDAQ:AMGNAmgen Inc
2024/11/1319:00PR Newswire (US)AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATANASDAQ:AMGNAmgen Inc
2024/11/0906:00PR Newswire (US)AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
2024/11/0816:00PR Newswire (US)TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPSNASDAQ:AMGNAmgen Inc
2024/11/0709:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
2024/11/0709:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
2024/11/0709:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
2024/11/0709:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
2024/11/0709:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
2024/10/3120:13IH Market NewsMicrosoft and Meta Decline Up to 4%; Roku Falls 14% Amid Lower Estimates; Booking Surges 6%; Carvana Soars 20%NASDAQ:AMGNAmgen Inc
2024/10/3105:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMGNAmgen Inc
2024/10/3105:01PR Newswire (US)AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTSNASDAQ:AMGNAmgen Inc
2024/10/2605:00PR Newswire (US)AMGEN ANNOUNCES 2024 FOURTH QUARTER DIVIDENDNASDAQ:AMGNAmgen Inc
2024/10/2505:00PR Newswire (US)AMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTSNASDAQ:AMGNAmgen Inc
2024/10/1521:00PR Newswire (US)AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024NASDAQ:AMGNAmgen Inc
2024/10/0122:00PR Newswire (US)LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFENASDAQ:AMGNAmgen Inc
2024/09/2605:45IH Market NewsDow, S&P Come Off Record Highs, Close On Weak NoteNASDAQ:AMGNAmgen Inc
2024/09/2505:00PR Newswire (US)TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASENASDAQ:AMGNAmgen Inc
2024/09/2405:00PR Newswire (US)AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASENASDAQ:AMGNAmgen Inc
 검색 관련기사 보기:NASDAQ:AMGN